SG10201912150TA - Anti-trem2 antibodies and methods of use thereof - Google Patents
Anti-trem2 antibodies and methods of use thereofInfo
- Publication number
- SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- trem2 antibodies
- trem2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238044P | 2015-10-06 | 2015-10-06 | |
| US201662369666P | 2016-08-01 | 2016-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912150TA true SG10201912150TA (en) | 2020-02-27 |
Family
ID=57178515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912150TA SG10201912150TA (en) | 2015-10-06 | 2016-10-06 | Anti-trem2 antibodies and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190330335A1 (https=) |
| EP (1) | EP3359569A2 (https=) |
| JP (2) | JP7725185B2 (https=) |
| KR (1) | KR20180068999A (https=) |
| CN (2) | CN117069841A (https=) |
| AU (2) | AU2016334051B2 (https=) |
| CA (1) | CA2997960A1 (https=) |
| SG (1) | SG10201912150TA (https=) |
| WO (1) | WO2017062672A2 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| CN109641961A (zh) | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CN110603550A (zh) * | 2016-12-13 | 2019-12-20 | 阿克利互动实验室公司 | 利用导航任务识别生物标志物和利用导航任务进行治疗的平台 |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| US10233226B2 (en) * | 2017-06-21 | 2019-03-19 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| JP2020530554A (ja) * | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| DK3601358T5 (da) * | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| AU2018352308B2 (en) * | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| AU2018383709B2 (en) * | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| EP3794027A4 (en) * | 2018-05-18 | 2022-02-09 | MacroGenics, Inc. | OPTIMIZED GP41 BINDING MOLECULES AND THEIR USES |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| CA3111569A1 (en) * | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| EP3861018A4 (en) * | 2018-10-05 | 2022-10-26 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | NEWBORN SCREENING FOR PRIMARY IMMUNODEFICIENCY CYSTINosis AND WILSON'S DISEASE |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| AU2019366960A1 (en) * | 2018-10-23 | 2021-05-27 | Regeneron Pharmaceuticals, Inc. | Fc silenced antibody drug conjugates (ADCs) and uses thereof |
| KR102156165B1 (ko) * | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| CA3120970A1 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| US12351629B2 (en) | 2018-12-10 | 2025-07-08 | Mor Research Applications Ltd. | TREM2 antibodies and uses thereof |
| KR20210104079A (ko) * | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| BR112021015656A2 (pt) * | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| JP7654202B2 (ja) * | 2019-02-28 | 2025-04-01 | ザ ロックフェラー ユニバーシティー | がんの予後及び治療におけるａｐｏｅ遺伝子型決定 |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| CN110320368A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| PH12022551228A1 (en) * | 2019-11-22 | 2023-06-14 | Lilly Co Eli | Trem2 antibodies and uses thereof |
| CN115003699A (zh) * | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| TWI888447B (zh) | 2019-12-13 | 2025-07-01 | 美商因思博納公司 | 金屬鹽及其用途 |
| WO2021146256A1 (en) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| JP2023512450A (ja) * | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP7745557B2 (ja) * | 2020-02-24 | 2025-09-29 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| JP2023519969A (ja) | 2020-03-31 | 2023-05-15 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | リソソーム蓄積症に関するプロテオミクススクリーニング |
| US12523662B2 (en) | 2020-04-02 | 2026-01-13 | Seattle Children's Hospital | Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia |
| IL296992A (en) | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| DK4172199T3 (da) * | 2020-06-26 | 2025-08-18 | Bioarctic Ab | Alfa-synuklein-protofibril-bindende antistoffer |
| JP2023536916A (ja) * | 2020-08-05 | 2023-08-30 | ビジル・ニューロサイエンス・インコーポレイテッド | Ｔｒｅｍ２アゴニストを使用した、コロニー刺激因子１受容体機能不全に関連する疾患の治療 |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
| US20240003918A1 (en) | 2020-11-30 | 2024-01-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| AU2021392813A1 (en) * | 2020-12-04 | 2023-06-29 | Vigil Neuroscience, Inc. | Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists |
| KR20230147617A (ko) * | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| CN112979795B (zh) * | 2021-02-26 | 2022-07-08 | 深圳市亚辉龙生物科技股份有限公司 | 抗体组合产品及其在新冠肺炎检测中应用 |
| US11904020B2 (en) * | 2021-03-19 | 2024-02-20 | Bicycletx Limited | Bicyclic peptide ligands specific for TREM2 |
| AU2022273303A1 (en) | 2021-05-14 | 2023-11-02 | Genentech, Inc. | Agonists of trem2 |
| WO2022245553A2 (en) * | 2021-05-19 | 2022-11-24 | Signablk, Inc. | Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof |
| IL285416A (en) * | 2021-08-05 | 2023-03-01 | Yeda Res & Dev | Antibodies for cancer treatment |
| CN118302445A (zh) * | 2021-08-20 | 2024-07-05 | 塔斯里夫制药有限责任公司 | 抗cd155抗体和抗原结合片段及其使用方法 |
| WO2023039450A2 (en) * | 2021-09-07 | 2023-03-16 | Duke University | Compositions and methods for treatment of retinal degeneration |
| AR127621A1 (es) * | 2021-11-09 | 2024-02-14 | Vigil Neuroscience Inc | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso |
| JP2025503437A (ja) | 2021-12-17 | 2025-02-04 | デナリ セラピューティクス インコーポレイテッド | ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド |
| EP4455275A4 (en) * | 2021-12-22 | 2026-03-18 | Univ Kagoshima | MACROPHAGE PRODUCTION METHOD, DIFFERENCE-INDUCING AGENT, DIFFERENCE-INDUCING KIT, MACROPHAGE CULTIVATION METHOD, MACROPHAGE PROPAGATION-PROMOTING AGENT, MACROPHAGE PROLIFERATION-PROMOTING KIT, MACROPHAGE PROLIFERATION METHOD, AND MACROPHAGES |
| CA3244298A1 (en) * | 2022-01-11 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL VARIANTS 2 (TREM2) AND ITS USES IN THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP4463484A4 (en) * | 2022-01-14 | 2026-02-25 | Qilu Puget Sound Biotherapeutics Corp | Anti-ccr8 antibodies |
| WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2023212707A2 (en) * | 2022-04-29 | 2023-11-02 | The Children's Medical Center Corporation | Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| WO2024182318A2 (en) * | 2023-02-28 | 2024-09-06 | Kodiak Sciences Inc. | Antibodies to htra1 and conjugates thereof |
| WO2024226569A1 (en) * | 2023-04-24 | 2024-10-31 | The Research Foundation For The State University Of New York | Immunogenicity screening method |
| WO2024253424A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| CN119735683B (zh) * | 2023-12-21 | 2025-10-31 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025194147A1 (en) * | 2024-03-15 | 2025-09-18 | The Children's Medical Center Corporation | Therapeutic modulation of trem2 and uses thereof in retinal degeneration |
| US12545729B2 (en) | 2024-06-27 | 2026-02-10 | Mabwell Therapeutics, Inc. | Anti-TREM2 agonist antibodies and antigen-binding fragments thereof that can increase levels of soluble TREM2 in serum and brain tissue |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| JP2004073182A (ja) * | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| WO2004058178A2 (en) * | 2002-12-23 | 2004-07-15 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| CN101120021A (zh) | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2701608A1 (en) * | 2007-10-05 | 2009-04-09 | University Of Maryland, Baltimore | Novel compositions and methods for stimulating erythropoiesis in a mammal |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| CN102770456B (zh) * | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2955086A1 (en) * | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
-
2016
- 2016-10-06 US US15/766,363 patent/US20190330335A1/en not_active Abandoned
- 2016-10-06 CN CN202310465565.6A patent/CN117069841A/zh active Pending
- 2016-10-06 WO PCT/US2016/055828 patent/WO2017062672A2/en not_active Ceased
- 2016-10-06 EP EP16784666.6A patent/EP3359569A2/en active Pending
- 2016-10-06 CN CN201680070761.1A patent/CN108738323B/zh active Active
- 2016-10-06 SG SG10201912150TA patent/SG10201912150TA/en unknown
- 2016-10-06 JP JP2018517785A patent/JP7725185B2/ja active Active
- 2016-10-06 KR KR1020187012495A patent/KR20180068999A/ko not_active Ceased
- 2016-10-06 CA CA2997960A patent/CA2997960A1/en active Pending
- 2016-10-06 AU AU2016334051A patent/AU2016334051B2/en active Active
-
2023
- 2023-02-17 US US18/171,291 patent/US20230295297A1/en active Pending
- 2023-04-04 JP JP2023060952A patent/JP2023093528A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200443A patent/AU2024200443A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3359569A2 (en) | 2018-08-15 |
| WO2017062672A2 (en) | 2017-04-13 |
| JP2018537956A (ja) | 2018-12-27 |
| AU2024200443A1 (en) | 2024-04-04 |
| JP7725185B2 (ja) | 2025-08-19 |
| WO2017062672A3 (en) | 2017-05-26 |
| US20190330335A1 (en) | 2019-10-31 |
| CN108738323A (zh) | 2018-11-02 |
| AU2016334051B2 (en) | 2023-10-26 |
| CA2997960A1 (en) | 2017-04-13 |
| CN117069841A (zh) | 2023-11-17 |
| AU2016334051A1 (en) | 2018-04-12 |
| US20230295297A1 (en) | 2023-09-21 |
| CN108738323B (zh) | 2023-05-26 |
| KR20180068999A (ko) | 2018-06-22 |
| JP2023093528A (ja) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| IL308156B1 (en) | Anti-C1S antibodies and methods of using them | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| IL259495A (en) | Antibodies and methods for using them | |
| IL257636A (en) | Anti-tigit antibodies and methods of use | |
| IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
| ZA201706323B (en) | Anti-pvrig antibodies and methods of use | |
| SG11201803567XA (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL259681A (en) | New antibodies against claudin and methods of using them | |
| ZA202001985B (en) | Anti-htra1 antibodies and methods of use thereof |